|Table of Contents|

Comparison of efficacy and analysis of factors affecting prognosis of malignant glioma treated with radiotherapy and concurrent chemoradiotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
607-612
Research Field:
Publishing date:

Info

Title:
Comparison of efficacy and analysis of factors affecting prognosis of malignant glioma treated with radiotherapy and concurrent chemoradiotherapy
Author(s):
TIAN Bi; SUN Xudong; MA Jian; LI Pengpeng; SHI Changli; DING Guangcheng; QIN Dehua; BU Yajing
Gamma Knife Center,the Fifth Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450000,China.
Keywords:
three-dimensional conformal radiation therapy; temozolomide; malignant glioma; prognosis; influencing factors
PACS:
R739.41
DOI:
10.3969/j.issn.1672-4992.2022.04.010
Abstract:
Objective:To investigate the prognostic factors of three-dimensional conformal radiation therapy (3DCRT) combined with temozolomide (TMZ) in the treatment of malignant glioma.Methods:The clinical data of 120 cases of malignant glioma patients in our hospital from January 2012 to June 2015 were retrospectively analysed.All patients underwent intracranial tumor resection,including 3DCRT in 56 patients (radiotherapy group),postoperative 3DCRT combined with TMZ oral treatment in 64 patients (chemoradiotherapy group).The efficacy of the two groups of treatment were compared,and survival analysis was performed using the Kaplan-Meier method,and univariate analysis and Cox regression multivariate analysis were used to investigate the independent influencing factors affecting the prognosis of patients with malignant glioma.Results:The 1-year survival rate and 2-year survival rate of the patients in the chemoradiotherapy group were 88.33% and 79.68%,respectively,which were significantly higher than that of the radiotherapy group (78.57%,55.36%,P＜0.05),and the median survival time of the chemoradiotherapy group was significantly longer than that of the radiotherapy group (28.4 months vs 21.3 months).The median progression-free survival (mPFS) of the chemoradiotherapy group was significantly longer than that of the radiotherapy group (20.1 months vs 16.5 months).The 1-year survival rate and 2-year survival rate of grade Ⅲ patients were 93.33% and 82.54%,respectively,which were significantly higher than those of grade Ⅳ patients (75.00%,54.29%,P＜0.05),and the median survival time of grade Ⅲ patients was significantly longer than that of grade Ⅳ (54.5 months vs 17.8 months).And the mPFS of grade Ⅲ patients was significantly longer than that of grade Ⅳ (32.4 months vs 14.6 months) (P＜0.05).Univariate analysis showed that age,pathological grade,preoperative KPS score,peritumoral edema,degree of surgical resection,tumor site,and number of lesions were significant factors affecting the median survival time of patients with malignant glioma(P＜0.05).Multivariate analysis results indicated that age,pathological grade,and preoperative KPS score were independent risk factors for postoperative survival in patients with malignant glioma.Conclusion:Radiotherapy combined with TMZ chemotherapy can significantly prolong the median survival of patients with malignant glioma.The prognosis of patients with malignant glioma is significantly correlated with age,pathological grade and preoperative KPS score.

References:

[1] MICHAEL C BURGER,MICHAEL W RONELLENFITSCH,NADJA I LORENZ,et al .Dabrafenib in patients with recurrent,BRAF V600E mutated malignant glioma and leptomeningeal disease［J］.Oncology Reports,2017,38(6):3291-3296.
[2] SHAO N,MAO J,XUE L,et al.Carnosic acid potentiates the anticancer effect of temozolomide by inducing apoptosis and autophagy in glioma［J］.Journal of Neuro-Oncology,2019,141(2):277-288.
[3] WOOLF EC,ROSSI AP,SILVANICHOLS HB,et al.Abstract 1125A:β-hydroxybutyrate inhibits histone deacetylase activity and radiosensitizes malignant glioma cells［J］.Cancer Research,2017,77(13):1125.
[4] DHAKAL A,POKHAREL S,WANG K,et al.Abstract 5709:Variation in Merlin expression and its prognostic significance in malignant pleural mesothelioma［J］.Cancer Research,2017,77(13 Supplement):5709.
[5]《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)［J］.中华医学杂志,2016,96(7):485-509. Compilation Group of "Guideline for Diagnosis and Treatment of Chinese Central Nervous System Gliomas".Guideline for diagnosis and treatment of Chinese central nervous system gliomas (2015) ［J］.Chinese Journal of Medical Science,2016,96(7):485- 509.
[6] CUSHMAN TR,VENIGALLA S,BROOKS ED,et al.Utilization of neoadjuvant intensity-modulated radiation therapy for rectal cancer in the United States［J］.Anticancer Res,2018,38(5):2923-2927.
[7] CHUN SG,HU C,CHOY H,et al.Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer:a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial［J］.Journal of Clinical Oncology,2017,35(1):56-62.
[8] LIU Huajie,LIU Bin,HOU Xianzeng,et al.Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma［J］.Journal of Neuro-Oncology,2017,132(3):409-417.
[9] SHAHBAZI AYAT YUSEF,ALIZADEH PAHLAVANI MOHAMMAD REZA.3D computation of no-load magnetic flux density in slotless axial-flux permanent-magnet synchronous machines using conformal mapping［J］.Iet Electric Power Applications,2017,11(8):1391-1396.
[10] ANJALI ARORA,KUMARAVEL SOMASUNDARAM.Glioblastoma vs temozolomide:can the red queen race be won［J］.Cancer Biology & Therapy,2019,20(8):1-8.
[11] SCOCCIANTI S,MAGRINI SM,RICARDI U,et al.Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)［J］.Neuro Oncol,2012,14(6):798-807.
[12]马文斌,郭旭,王任直.美国NCCN神经系统肿瘤治疗指南(2008)的介绍及解读［J］.中国神经精神疾病杂志,2009,35(6):323-326. MA WB,GUO X,WANG RZ.Introduction and interpretation of NCCN guidelines for the treatment of neurological tumors in the United States (2008) ［J］.Chinese Journal of Neuropsychiatric Diseases,2009,35(6):323-326.
[13]薛湛,李德岭,李桂林,等.影响多中心脑胶质瘤患者预后的因素分析［J］.中华神经外科杂志,2017,33(3):234-238. XUE Z,LI DL,LI GL,et al.Analysis of factors affecting the prognosis of patients with multicentric glioma ［J］.Chinese Journal of Neurosurgery,2017,33(3):234-238.
[14]张东旭,曲彦明,张明山,等.WHO Ⅱ级脑胶质瘤患者无进展生存期的影响因素分析［J］.中华神经外科杂志,2019,35(5):469-473. ZHANG DX,QU YM,ZHANG MS,et al.Influencing factors of progression-free survival in patients with WHO grade Ⅱ glioma ［J］.Chinese Journal of Neurosurgery,2019,35(5):469-473.
[15] Hua LIN,SHAAN PATEL,VALERIE S AFFLECK,et al.Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells［J］.Neuro-Oncology,2016,19(1):43-54.
[16]王敏红,冯湛.瘤周水肿常规MRI纹理分析鉴别脑胶质母细胞瘤和单发转移瘤的价值［J］.中华放射学杂志,2018,52(10):756-760. WANG MH,FENG Z.Value of conventional MRI texture analysis of peritumoral edema to distinguish glioblastoma and single metastases ［J］.Chinese Journal of Radiology,2018,52(10):756-760.
[17]左频,陈芸,罗林,等.恶性脑胶质瘤患者MGMT基因启动子甲基化状态与预后相关性［J］.中华肿瘤防治杂志,2019，26(1):30-36. ZUO B,CHEN Y,LUO L,et al.Correlation between MGMT gene promoter methylation status and prognosis in patients with malignant glioma ［J］.Chinese Journal of Cancer Prevention and Treatment,2019,26(1):30-36.
[18]王伟,刘娟.三维适形放疗联合替莫唑胺化疗对恶性脑胶质瘤患者术后不良反应发生率及生存质量的影响［J］.中国地方病防治杂志,2017,32(10):1183-1185 WANG W,LIU J.Effect of three-dimensional conformal radiotherapy combined with temozolomide chemotherapy on the incidence of adverse reactions and quality of life in patients with malignant glioma ［J］.Chinese Journal of Endemic Diseases Prevention and Treatment,2017,32(10):1183-1185.
[19] VENITA JAY,JAMES RUTKA,LAURENCE E BECKER,et al.Pediatric malignant glioma with tubuloreticular inclusions and MYCN amplification.Report of a case with immunohistochemical,ultrastructural,flow cytometric,karyotypic,and southern blot analysis［J］.Cancer,2015,73(7):1987-1993.

Memo

Memo:
-
Last Update: 1900-01-01